Bina Tejura, MD

Senior Medical Director
Seres Therapeutics
Cambridge, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• 74 - Clinical and Microbiology Outcomes of Bloodstream Infections (BSI) in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HCT) in a Randomized, Double-blind, Placebo-controlled Cohort 2 of a Phase 1b Study of SER-155, an Investigational Live Biotherapeutic

  Monday, October 20, 2025
  10:30 AM - 10:42 AM US ET